Fred Hutchinson Cancer Center leads the way when it comes to offering eligible patients alternative options when conventional therapies no longer work. With more than two dozen phase 1 clinical trials ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
71% (12/17) showed a decrease in Total Symptom Score (TSS). 53% (9/17) showed a ≥50% decrease in TSS. Patients with all genotypes identified in the study (CALR, JAK2 V617F, Triple Negative) responded ...
Success by nearly all measures with Praxis Precision Medicines Inc.’s essential tremor phase III candidate, ulixacaltamide, drove the company’s stock up by more than 200% and provided supportive data ...
The initiation of a second Phase 3 clinical trial for bomedemstat demonstrates company’s commitment to advancing research in myeloproliferative neoplasms (MPNs) RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a global leader ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results